Print this page
Friday, December 23, 2016 Written by Dr. Charlotte A. Gaydos

Cepheid Xpert® CT/NG: An exciting and promising new point-of-care rapid test to address the epidemic of Chlamydia and Gonorrhea

Real-World Workshop Series Webinar - November 2012

Presenter: Dr. Charlotte A. Gaydos

Hear Dr. Charlotte Gaydos discuss Cepheid’s Xpert® CT/NG test*, a promising new rapid test to address the epidemic of Chlamydia and Gonorrhea.

Chlamydia trachomatis (CT) infection is the most common bacterial sexually transmitted infection (STI) in the United States, with >2,800,000 new cases estimated to occur annually. In 2010, 1.3 million cases were reported to the CDC. Neisseria gonorrhoeae (NG) is the second most prevalent bacterial STI with an estimated 700,000 infections occurring annually, and with 309,341 cases reported in 2010. Both of these infections can result in pelvic inflammatory disease (PID), which can cause serious and costly sequelae (infertility, ectopic pregnancy, and chronic pelvic pain) in women.



*Xpert CT/NG is CE-IVD marked and not available for sale in the USA.